Acute respiratory distress syndrome (ARDS) is a lung disease with a high mortality rate and difficult recovery. Pneumonia, inhalation, and drowning are all contributing factors to ARDS. How effectively surfactant is delivered to the lungs is key to alleviating the disease. Currently, due to the lack of effective treatment options for ARDS, care and rehabilitation are entirely dependent on mechanical ventilation. Professor Yan Ostrovski of Israel has developed a liquid foam as a drug carrier based on existing intubation methods, called “liquid foam therapy” (LIFT), in which an automated device pushes the foam into the lungs to distribute it evenly and sufficiently. This method offers advantages such as uniform distribution, unlimited dose, high penetration, and low cost of treatment. It can also be used in the future for lung delivery of stem cells and to address the entire market.